Why the study?
Does triple antiplatelet therapy reduce enzymatic infarct size compared to dual antiplatelet therapy in patients with NSTE ACS planned for early catheterization?
Population
328 consecutive patients with non-ST-elevation acute coronary syndrome planned for early catheterization
Comparison
Triple antiplatelet therapy as pre-treatment vs Dual antiplatelet therapy as pre-treatment
Design
RCT, randomized
Follow-up
30 days
Authors
Loading...
Triple antiplatelet therapy does not reduce enzymatic infarct size in NSTE-ACS; challenges routine tirofiban pre-treatment before early catheterization.
Does triple antiplatelet therapy reduce enzymatic infarct size compared to dual antiplatelet therapy in patients with NSTE ACS planned for early catheterization?
In patients with NSTE ACS planned for early catheterization, triple antiplatelet pre-treatment including tirofiban did not significantly reduce enzymatic infarct size but improved initial culprit vessel perfusion compared to dual antiplatelet therapy.
Saman Rasoul (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: